Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.O)

CYCC.O on Consolidated Issue listed on NASDAQ Capital Market

1.91USD
21 Jul 2017
Change (% chg)

$0.20 (+11.70%)
Prev Close
$1.71
Open
$1.72
Day's High
$1.91
Day's Low
$1.72
Volume
2,640,990
Avg. Vol
701,524
52-wk High
$10.90
52-wk Low
$1.71

Latest Key Developments (Source: Significant Developments)

Cyclacel Pharma files for potential offering of up to $15 mln
Friday, 26 May 2017 05:18pm EDT 

May 26 (Reuters) - Cyclacel Pharmaceuticals Inc :Cyclacel pharmaceuticals inc- files for potential offering of up to $15 million - sec filing.  Full Article

Cyclacel Pharmaceuticals Q1 loss per share $0.38
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Cyclacel Pharmaceuticals Inc ::Cyclacel pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.38.  Full Article

Cyclacel Pharmaceuticals reports Q4 and full year 2016 financial results
Tuesday, 28 Mar 2017 04:05pm EDT 

Cyclacel Pharmaceuticals Inc - : Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results . Says net loss for three months and year ended December 31, 2016 was $2.8 million and $11.8 million respectively .Says revenue for three months and year ended December 31, 2016 were $0.3 million and $0.8 million respectively.  Full Article

Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia
Thursday, 23 Feb 2017 06:57am EST 

Cyclacel Pharmaceuticals Inc : Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia . Cyclacel Pharmaceuticals Inc - study did not reach statistically significant improvement in primary endpoint of overall survival . Cyclacel Pharmaceuticals Inc - improvement in secondary endpoint of complete remission rate for experimental arm . Cyclacel Pharmaceuticals Inc says cash resources are projected to fund these activities and operations through end of 2018 . Cyclacel Pharmaceuticals Inc - cash resources are projected to fund these activities and operations through end of 2018 .Cyclacel Pharmaceuticals-plan to discuss data from seamless with european, us regulators once subgroup analyses are completed in next few months.  Full Article

Tang Capital Partners Lp says 9.6 pct stake in Cyclacel Pharmaceuticals
Friday, 19 Aug 2016 05:54pm EDT 

Tang Capital Partners Lp:Tang Capital Partners Lp reports 9.6 pct passive stake in Cyclacel Pharmaceuticals Inc as of Aug 12 - SEC Filing.  Full Article

Cyclacel Pharma Q2 shr loss $1.01
Wednesday, 10 Aug 2016 04:05pm EDT 

Cyclacel Pharmaceuticals Inc : Cyclacel pharmaceuticals reports 2nd quarter 2016 financial results . Cyclacel pharmaceuticals q2 shr loss $1.01 . Cyclacel pharmaceuticals q2 revenue $200,000 vs $300,000 .Cyclacel says estimates that it has capital resources to reach beyond final analysis of seamless and continue existing programs through q1 of 2018.  Full Article

Cyclacel Pharmaceuticals may issue, sell shares having aggregate offering price of up to $4 mln through FBR
Thursday, 23 Jun 2016 05:21pm EDT 

Cyclacel Pharmaceuticals Inc :Sales agreement with FBR Capital Markets & Co; may issue, sell shares having aggregate offering price of up to $4 million through FBR.  Full Article

Cyclacel Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing
Friday, 10 Jun 2016 04:48pm EDT 

Cyclacel Pharmaceuticals Inc : Files for mixed shelf of up to $100 million - sec filing Source: (http://1.usa.gov/1WIQTTw ) Further company coverage: [CYCC.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Cyclacel Pharmaceuticals reports Q1 loss per share $0.09
Wednesday, 11 May 2016 04:05pm EDT 

Cyclacel Pharmaceuticals Inc : Cyclacel Pharmaceuticals Inc says estimates that it has capital resources to reach beyond final analysis of seamless and continue existing programs through end of 2017 . Cyclacel Pharmaceuticals reports first quarter 2016 financial results . Q1 loss per share $0.09 .Q1 revenue $100,000 versus $500,000.  Full Article

Cyclacel Pharmaceuticals Inc presents molecular rationale for clinical development of cyc065 cdk inhibitor in leukemias and lymphomas
Thursday, 17 Sep 2015 07:00am EDT 

Cyclacel Pharmaceuticals Inc:Presents molecular rationale for clinical development of cyc065 cdk inhibitor in leukemias and lymphomas.Says cyc065 cleared by FDA for first-in-human phase 1 clinical trial.  Full Article